Clinical Trials
4 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT05910112 2023-06-18
PROSPECT
University of Oxford
Unknown
NCT00899613 2009-12-15
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
National Cancer Institute (NCI)
Unknown